According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

AEMD READ THE FULL AEMD RESEARCH REPORT Patient enrollments begin for AEMD’s basket oncology trial Aethlon Medical (NASDAQ:AEMD) announced FY 2Q results and provided a business update yesterday. The ...

The ASX rises on positive US inflation news, Xero ticks up 5% and Bitcoin hits US$93k before cooling off a tad.

The ASX rose, led by Xero, while goldies slid. Variscan surged 50pc, Asian stocks dropped, and Bitcoin hit $93k before ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

For Keytruda, "the cost-effectiveness estimates are higher than NICE normally considers an acceptable use of NHS resources," said the agency. Somewhat unusually, it said it would also like to see ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...